Amplitude Healthcare Acquisition Corp: insider trades · United States · SEC (Form 4)

About Amplitude Healthcare Acquisition Corp

Jasper Therapeutics, Inc. (Nasdaq: JSPR) is a U.S.-listed biotechnology company headquartered in Redwood City, California, United States. Although your prompt references Amplitude Healthcare Acquisition Corp, that entity was originally a 2019 special purpose acquisition company (SPAC) and became the public listing vehicle for Jasper Therapeutics after the business combination closed in September 2021. The company now trades on the NASDAQ and operates as a clinical-stage biotech focused on mast-cell–driven diseases and hematopoietic stem cell transplant-related therapies. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1788028/000121390021043115/R7.htm?utm_source=openai)) Amplitude was formed to pursue life-science acquisition opportunities, but its role changed materially once it merged with Jasper Therapeutics. After the transaction closed on September 24, 2021, the combined company began trading under the ticker JSPR. From an investor perspective, this matters because the business profile is no longer that of a SPAC shell; it is now a development-stage biopharmaceutical company whose valuation is driven by clinical execution, regulatory progress, and capital access rather than product sales. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1788028/000121390021043115/R7.htm?utm_source=openai)) Jasper’s lead asset is briquilimab, a monoclonal antibody targeting c-Kit (CD117). The program is being developed for mast-cell–mediated conditions, including chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), and allergic asthma. Jasper’s recent corporate updates indicate that the company has been advancing dose selection work for a planned Phase 2b CSU study, while also evaluating and expanding its broader clinical package in mast-cell-driven diseases. In practical terms, the investment case is centered on whether briquilimab can generate differentiated clinical data and support a path toward later-stage development. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1788028/000121390026056596/ea029079201ex99-1.htm?utm_source=openai)) The company’s competitive position should be viewed in the context of a highly competitive biotech landscape. Jasper is a niche innovator rather than a diversified pharmaceutical group. Its potential edge lies in a focused mechanism of action, a pipeline concentrated on immunology/inflammation, and a development strategy aimed at high-value orphan or specialty indications. At the same time, the company remains exposed to the standard risks for small-cap clinical biotech names: trial uncertainty, reimbursement and regulatory risk, and a continuing reliance on external financing. Jasper explicitly flagged financing needs and, in 2025, announced a workforce reduction to extend its cash runway, followed by an equity offering later in the year. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001788028/000121390025062194/ea024839401ex99-1_jasper.htm?utm_source=openai)) Geographically, Jasper is based in California and operates primarily from its Redwood City headquarters. The business is still largely U.S.-centric from an operating standpoint, with its clinical and corporate footprint tied to the United States. For French, Belgian, and Swiss investors, the key takeaway is that JSPR is a NASDAQ-listed United States biotech story with meaningful upside tied to pipeline data, but with elevated volatility and financing sensitivity typical of early-stage healthcare equities. ([sec.gov](https://www.sec.gov/Archives/edgar/data/0001788028/000121390026036426/ea0282128-10k_jasper.htm?utm_source=openai))